Author

M. A. Nakano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:cell signaling & trafficking· 2 Assay:proteomics· 2 Research Focus:clustering· 1

Frequent Co-Authors

D. Yamashita· 4 shared I. Nakano· 4 shared H. Kornblum· 3 shared M. S. Pavlyukov· 3 shared D. Crossman· 2 shared D.-H. Nam· 2 shared M. Gorospe· 2 shared R. Kawaguchi· 2 shared

Activity by Year

2020-2020 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

D. Yamashita

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Spatiotemporal Dynamics of Intra-tumoral Dependence on NEK2-EZH2 Signaling in Glioblastoma Cancer Progression

J. Wang, M. S. Pavlyukov, D. Yamashita, P. Cheng, Z. Zhang, S.-H. Kim, M. A. Nakano, W. Xie, D. Chen, B. Frett, W.-h. Hu, Y. J. Shin, Y. Lee, V. Goidts, D.-H. Nam, , I. Nakano

This study identifies NEK2-EZH2 signaling as critical for glioblastoma tumor core progression and resistance, and presents a novel inhibitor CMP3a that shows therapeutic potential.

bioRxiv · Dec 1, 2020 · PreprintCancer Biology

Spatial heterogeneity of glioblastoma cells reveals sensitivity to NAD+ depletion at tumor edge

D. Yamashita, D. Botta, H. J. Cho, X. Guo, S. Ozaki, V. L. Flanary, I. Sirota, M. Gao, S. Yamaguchi, M. A. Nakano, F. Zhou, H. Zhou, T. Kondo, T. Kunieda, D. Crossman, , I. Nakano

This study identifies clonal subpopulations in glioblastoma core and edge lesions and shows that NAD+ depletion via CD38 inhibition reduces tumor edge formation.

bioRxiv · Nov 26, 2020 · PreprintCancer Biology

Endothelial-secreted Endocan protein acts as a PDGFR alpha ligand and regulates vascularity, radioresistance, and regional phenotype in glioblastoma

S. Bastola, M. S. Pavlyukov, Y. Ghochani, N. Sharma, M. A. Nakano, D. Muthukrishnan, S. Y. Yu, M. S. Kim, A. Sohrabi, N. P. Biscola, D. Yamashita, K. Anufrieva, R. Kawaguchi, Y. Qin, S. K. Seidlits, , H. Kornblum

This study identifies Endocan as an endothelial-secreted ligand for PDGFR alpha that promotes GBM vascularity, radioresistance, and phenotypic diversity.

bioRxiv · Oct 12, 2020 · PreprintCancer Biology

Brain aging-dependent glioma traits reversible by NAD+/BDNF-mediated neuronal reactivation

D. Yamashita, V. L. Flanary, R. B. Munk, K. Sonomura, S. Ozaki, R. Kawaguchi, S. Suehiro, S. Bastola, M. S. Pavlyukov, S. Yamaguchi, M. A. Nakano, T. Kunieda, D. Hambardzumyan, T. Kondo, H. Kornblum, , I. Nakano

This study shows that aging reduces neuronal signaling in gliomas, but NAD+ and BDNF can reverse these effects, improving outcomes in older mice.

bioRxiv · Oct 10, 2020 · PreprintCancer Biology